Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

NCT01371604 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: IDX184
BIOLOGICAL: Peginterferon alfa-2a (Peg-IFN)
DRUG: Ribavirin (RBV)
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC